​

Mark is responsible for the identification and execution of drug discovery programs under Evotec´s academic BRIDGE umbrella. Mark works closely with investigators across universities to identify interesting, promising opportunities and help shape these programs. Mark brings a wealth of expertise in drug discovery into this role with over 15 years in the drug discovery arena across many therapeutic areas, target classes also in the context of new spinouts through to large pharma. Extending the success of the academic BRIDGE model to other leading institutes across Europe is also one of Mark´s areas of responsibilities.

​

Prior to his current role, Mark was VP In vitro pharmacology responsible for drug discovery activities within the context of Evotec´s Execute and Innovate business segments. During this time Mark saw the development of several programs now in Phase 1 and Phase 2 clinical testing and was also pivotal in introducing key technologies into the company.